Abstract
Primary renal manifestations of diffuse large B-cell lymphoma (PR-DLBCL) represent an exceptionally rare variant of the most common type of non-Hodgkin lymphoma (NHL). Insights into PR-DLBCL pathogenesis have been limited to small case series and methodologically limited approaches. The mechanisms driving lymphomagenesis within an organ lacking an intrinsic lymphatic niche and its proclivity for dissemination to immune-privileged sites, including testes and central nervous system, remain poorly understood. To decode the genetic and transcriptional framework of PR-DLBCL, we utilized whole exome sequencing, array-based somatic copy number alterations analysis, and RNA sequencing. Hereby we characterize the most extensive cohort of PR-DLBCL published, comprising 34 samples from 30 patients. Despite significant mutational heterogeneity with a broad distribution among molecular clusters, we observed a strong unifying enrichment in deleterious MHC class I and II aberrations and loss of CDKN2A at a frequency similar to primary large B-cell lymphoma of immune privileged sites (IP-LBCL) alongside significant transcriptional deregulation of interferon signaling and MYC targets in MHC class I-deficient cases.
Our integrative assessment of PR-DLBCL biology expands the molecular understanding of this rare variant including similarities with IP-LBCL as an intriguing explanation for its clinical behavior and tropism. Our observations may inform future risk-adapted therapeutic approaches.
Competing Interest Statement
Niklas Gebauer received travel support from Beigene, Janssen, and Roche as well as honoraria from Roche, Takeda, Janssen, Menarini Stemline, and AstraZeneca.
Funding Statement
Wilhelm Sander-Stiftung HB and AK acknowledge support from the BMBF project OUTLIVE-CRC (FKZ 01KD2103A)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
ethics committee of the University of Luebeck gave ethical approval of this work (reference-no 18-356). This study was conducted per the declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interests: Niklas Gebauer received travel support from Beigene, Janssen, and Roche as well as honoraria from Roche, Takeda, Janssen, Menarini Stemline, and AstraZeneca.
↵** Shared senior authorship
Data Availability
All data produced in the present work are contained in the manuscript
